Overview

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System

Status:
Terminated

Trial end date:
2013-04-15

Target enrollment:

Participant gender:

Summary

The primary objective is to compare fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving immunosuppressive therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Europe Ltd.

Collaborator:

Cubist Pharmaceuticals LLC

Treatments:

Fidaxomicin
Vancomycin